7MN6 image
Entry Detail
PDB ID:
7MN6
EMDB ID:
Title:
Structure of the HER2 S310F/HER3/NRG1b Heterodimer Extracellular Domain
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2021-04-30
Release Date:
2021-10-27
Method Details:
Experimental Method:
Resolution:
3.09 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Receptor tyrosine-protein kinase erbB-3
Chain IDs:A
Chain Length:1066
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Receptor tyrosine-protein kinase erbB-2,Maltose/maltodextrin-binding periplasmic protein
Mutations:S310F
Chain IDs:B
Chain Length:1455
Number of Molecules:1
Biological Source:Homo sapiens, Escherichia coli
Polymer Type:polypeptide(L)
Description:Isoform 6 of Pro-neuregulin-1, membrane-bound isoform
Chain IDs:C (auth: H)
Chain Length:87
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Structures of the HER2-HER3-NRG1 beta complex reveal a dynamic dimer interface.
Nature 600 339 343 (2021)
PMID: 34759323 DOI: 10.1038/s41586-021-04084-z

Abstact

Human epidermal growth factor receptor 2 (HER2) and HER3 form a potent pro-oncogenic heterocomplex1-3 upon binding of growth factor neuregulin-1β (NRG1β). The mechanism by which HER2 and HER3 interact remains unknown in the absence of any structures of the complex. Here we isolated the NRG1β-bound near full-length HER2-HER3 dimer and, using cryo-electron microscopy, reconstructed the extracellulardomain module, revealing unexpected dynamics at the HER2-HER3 dimerization interface. We show that the dimerization arm of NRG1β-bound HER3 is unresolved because the apo HER2 monomer does not undergo a ligand-induced conformational change needed to establish a HER3 dimerization arm-binding pocket. In a structure of the oncogenic extracellular domain mutant HER2(S310F), we observe a compensatory interaction with the HER3 dimerization arm that stabilizes the dimerization interface. Both HER2-HER3 and HER2(S310F)-HER3 retain the capacity to bind to the HER2-directed therapeutic antibody trastuzumab, but the mutant complex does not bind to pertuzumab. Our structure of the HER2(S310F)-HER3-NRG1β-trastuzumab Fab complex reveals that the receptor dimer undergoes a conformational change to accommodate trastuzumab. Thus, similar to oncogenic mutations, therapeutic agents exploit the intrinsic dynamics of the HER2-HER3 heterodimer. The unique features of a singly liganded HER2-HER3 heterodimer underscore the allosteric sensing of ligand occupancy by the dimerization interface and explain why extracellular domains of HER2 do not homo-associate via a canonical active dimer interface.

Legend

Protein

Chemical

Disease

Primary Citation of related structures